Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Relay Therapeutics, Inc. reported revenue of $15M, up 53.4% year over year. Operating margin was -1971.6% and net margin -1800.6%, on a free-cash-flow margin of -1536.1% with capital expenditure at 2.7% of revenue. Every figure is computed directly from RLAY's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $15M | -1971.6% | -1800.6% |
| FY2024 | $10M | -3722.1% | -3374.7% |
| FY2023 | $26M | -1460.1% | -1338.7% |
| FY2022 | $1M | -21670.9% | -21036.1% |
| FY2021 | $3M | -12040.2% | -12012.9% |
How does RLAY compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.